FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2895854040> ?p ?o ?g. }

• W2895854040 abstract "Phase 3 trials have shown that nintedanib reduces the decline in forced vital capacity (FVC) in patients with mild-to-moderate idiopathic pulmonary fibrosis (IPF) with acceptable safety profiles; however, its effects on advanced IPF are unclear. We investigated the efficacy and safety of nintedanib in patients with advanced IPF.Prospective data were obtained from 108 IPF patients administered at least one dose of nintedanib. Of these patients, 47.2% had advanced IPF (FVC < 50% predicted, or diffusing capacity < 30% predicted).The median treatment duration was 42.2 weeks. Nintedanib significantly reduced the decline rate in both FVC (- 0.55% [before] vs. -0.32% [after] predicted/month, p = 0.020) and total lung capacity (TLC) (- 0.35% vs. -0.06% predicted/month, p < 0.001) in all patients. A significant improvement in FVC decline rate after treatment was also observed in the advanced group (- 0.77% vs. -0.22% predicted/month, p = 0.003), but not in the non-advanced group (- 0.41% vs. -0.33% predicted/month, p = 0.564). Adverse events occurred in 97.2% of the cohort, including diarrhoea (50.0%) and anorexia (45.4%). Following adjustment for treatment duration, no inter-group difference in odds ratio was observed for the occurrence of adverse events. However, the advanced group showed a higher frequency of treatment interruption (68.0% vs. 40.0%), mainly as a result of disease progression (47.1% vs. 36.4%).The efficacy and safety profiles of nintedanib in the advanced group were comparable to those in the non-advanced group except for a higher frequency of discontinuation, which may be due to the advanced status itself." @default.
• W2895854040 created "2018-10-26" @default.
• W2895854040 creator A5000804673 @default.
• W2895854040 creator A5032537844 @default.
• W2895854040 creator A5055570107 @default.
• W2895854040 creator A5074467983 @default.
• W2895854040 date "2018-10-19" @default.
• W2895854040 modified "2023-10-18" @default.
• W2895854040 title "Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis" @default.
• W2895854040 cites W1757222072 @default.
• W2895854040 cites W1964124382 @default.
• W2895854040 cites W2042146535 @default.
• W2895854040 cites W2045756883 @default.
• W2895854040 cites W2066138662 @default.
• W2895854040 cites W2069724928 @default.
• W2895854040 cites W2079988825 @default.
• W2895854040 cites W2080831548 @default.
• W2895854040 cites W2089756110 @default.
• W2895854040 cites W2106320546 @default.
• W2895854040 cites W2106408170 @default.
• W2895854040 cites W2117488044 @default.
• W2895854040 cites W2120791222 @default.
• W2895854040 cites W2122415095 @default.
• W2895854040 cites W2125078269 @default.
• W2895854040 cites W2138871107 @default.
• W2895854040 cites W2141922649 @default.
• W2895854040 cites W2145106519 @default.
• W2895854040 cites W2152974152 @default.
• W2895854040 cites W2157869208 @default.
• W2895854040 cites W2167383172 @default.
• W2895854040 cites W2462000645 @default.
• W2895854040 cites W2469138893 @default.
• W2895854040 cites W2507379588 @default.
• W2895854040 cites W2510319197 @default.
• W2895854040 cites W2524005801 @default.
• W2895854040 cites W2561981946 @default.
• W2895854040 cites W2597638604 @default.
• W2895854040 cites W2748660768 @default.
• W2895854040 cites W2766726468 @default.
• W2895854040 cites W2767378828 @default.
• W2895854040 cites W2768006414 @default.
• W2895854040 cites W2788452276 @default.
• W2895854040 cites W2790223305 @default.
• W2895854040 cites W4245666729 @default.
• W2895854040 doi "https://doi.org/10.1186/s12931-018-0907-8" @default.
• W2895854040 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6194688" @default.
• W2895854040 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30340638" @default.
• W2895854040 hasPublicationYear "2018" @default.
• W2895854040 type Work @default.
• W2895854040 sameAs 2895854040 @default.
• W2895854040 citedByCount "55" @default.
• W2895854040 countsByYear W28958540402019 @default.
• W2895854040 countsByYear W28958540402020 @default.
• W2895854040 countsByYear W28958540402021 @default.
• W2895854040 countsByYear W28958540402022 @default.
• W2895854040 countsByYear W28958540402023 @default.
• W2895854040 crossrefType "journal-article" @default.
• W2895854040 hasAuthorship W2895854040A5000804673 @default.
• W2895854040 hasAuthorship W2895854040A5032537844 @default.
• W2895854040 hasAuthorship W2895854040A5055570107 @default.
• W2895854040 hasAuthorship W2895854040A5074467983 @default.
• W2895854040 hasBestOaLocation W28958540401 @default.
• W2895854040 hasConcept C126322002 @default.
• W2895854040 hasConcept C165637977 @default.
• W2895854040 hasConcept C197934379 @default.
• W2895854040 hasConcept C2777543607 @default.
• W2895854040 hasConcept C2777714996 @default.
• W2895854040 hasConcept C2778341716 @default.
• W2895854040 hasConcept C2780171596 @default.
• W2895854040 hasConcept C3018587741 @default.
• W2895854040 hasConcept C55520419 @default.
• W2895854040 hasConcept C71924100 @default.
• W2895854040 hasConcept C90924648 @default.
• W2895854040 hasConceptScore W2895854040C126322002 @default.
• W2895854040 hasConceptScore W2895854040C165637977 @default.
• W2895854040 hasConceptScore W2895854040C197934379 @default.
• W2895854040 hasConceptScore W2895854040C2777543607 @default.
• W2895854040 hasConceptScore W2895854040C2777714996 @default.
• W2895854040 hasConceptScore W2895854040C2778341716 @default.
• W2895854040 hasConceptScore W2895854040C2780171596 @default.
• W2895854040 hasConceptScore W2895854040C3018587741 @default.
• W2895854040 hasConceptScore W2895854040C55520419 @default.
• W2895854040 hasConceptScore W2895854040C71924100 @default.
• W2895854040 hasConceptScore W2895854040C90924648 @default.
• W2895854040 hasIssue "1" @default.
• W2895854040 hasLocation W28958540401 @default.
• W2895854040 hasLocation W28958540402 @default.
• W2895854040 hasLocation W28958540403 @default.
• W2895854040 hasLocation W28958540404 @default.
• W2895854040 hasOpenAccess W2895854040 @default.
• W2895854040 hasPrimaryLocation W28958540401 @default.
• W2895854040 hasRelatedWork W2726643436 @default.
• W2895854040 hasRelatedWork W2747720470 @default.
• W2895854040 hasRelatedWork W2921352727 @default.
• W2895854040 hasRelatedWork W3087600456 @default.
• W2895854040 hasRelatedWork W3139014258 @default.
• W2895854040 hasRelatedWork W3163230142 @default.
• W2895854040 hasRelatedWork W3163296987 @default.
• W2895854040 hasRelatedWork W3164444235 @default.
• W2895854040 hasRelatedWork W4291743724 @default.

• next